May 3, 2021 - Kitchener, ON:
Intellijoint Surgical Inc. has gained market authorization from the Japanese Pharmaceutical and Medical Device Agency (PMDA) for Intellijoint HIP® and will begin distribution in Japan through a well-established partner in that market . Intellijoint HIP is an easy-to-use, surgeon-controlled navigation system that provides real-time measurements to optimize implant alignment and positioning during hip replacement surgery.
“Gaining entry into the largest computer-assisted surgical navigation market is a major milestone for our team” says Armen Bakirtzian, Co-founder and CEO at Intellijoint. “We are marching forward on our mission to improve patients' lives by providing every surgeon with effective, easy-to-use technology.”
Intellijoint HIP is already available in the United States, Canada and Australia and earlier this year had surpassed use in 20,000 hip surgeries since its launch in 2016 . The first cases in Japan are expected in May.
Intellijoint Surgical was featured on the Deloitte Technology Fast 50™ Companies list for two consecutive years, ranking 1st (2020) and 2nd (2019). We are excited to continue that rapid growth by entering the world’s largest computer-assisted surgical navigation market in the world.
About Intellijoint Surgical:
Intellijoint Surgical® develops and commercializes surgical navigation solutions for total joint replacements. It is committed to improving patients’ lives by providing every surgeon with effective, easy-to-use technology. Intellijoint HIP® and Intellijoint KNEE® smart navigation applications are both delivered through the Intellijoint Navigation System®. It is a fast and easy-to-use, surgeon-controlled system that provides real-time measurements to optimize implant alignment and positioning during total hip and knee replacement surgery to help improve patient outcomes.
Intellijoint also appeared on the Globe and Mail’s Canada Top Growing Companies List (37th, 2020) and the 2019 Startup 50 List of Canada’s Top New Growth Companies by Canadian Business and Maclean’s (13th, 2019) among other awards over the years.